Veeva Systems || OpenData
Enquire now and stand a chance to win exclusive gifts!
Enquire now and stand a chance to win exclusive gifts!
Enquire now and stand a chance to win exclusive gifts!
Enquire now and stand a chance to win exclusive gifts!
Enquire now and stand a chance to win exclusive gifts!
Enquire now and stand a chance to win exclusive gifts!

A Novel Oral Therapy Discovered to Treat Adult Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Blueprint Medicines Corporation discovered GAVRETO™ for the treatment of adult patients with metastatic Rearranged during Transfection (RET) fusion-positive Non-small Cell Lung Cancer (NSCLC).

GAVRETO an oral, RET-targeted therapy is taken daily twice. The oral therapy is designed to selectively and potently inhibit RET alterations which gives rise to many types of cancers, including approximately 1 to 2 percent of patients with NSCLC.

GAVRETO™ oral therapy makes a potential benefit in changing standards of care for patients with RET fusion-positive non-small cell lung cancer, where the treatments for patients are limited.

Some of the major side effects with GAVRETO include interstitial lung disease/pneumonitis, hypertension, hepatotoxicity, hemorrhagic events, risk of impaired wound healing and risk of embryo-fetal toxicity.

U.S. Food and Drug Administration (FDA) has approved GAVRETO™ (pralsetinib) for the treatment of adult patients with metastatic RET fusion-positive Non-small Cell Lung Cancer (NSCLC).

Latest Issue
Get instant
access to our latest e-book
Lonza Capsugel® Zephyr™ Dry-Powder Inhalation Capsule Portfolio Kerry || Webinar || Regulatory Considerations Regarding IR Film Coating Post-Approval Changes Meco - 90 years Medical Fair Thailand 2022